← Browse by Condition
Medical Condition

de novo myelodysplastic syndrome

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for de novo myelodysplastic syndrome sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — de novo myelodysplastic syndrome Clinical Trials

How many clinical trials are currently recruiting for de novo myelodysplastic syndrome?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for de novo myelodysplastic syndrome, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for de novo myelodysplastic syndrome?
de novo myelodysplastic syndrome research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a de novo myelodysplastic syndrome clinical trial?
Eligibility criteria for de novo myelodysplastic syndrome trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
M.D. Anderson Cancer Center 2 trials

Recruiting Clinical Trials

NCT01624805 Phase 2
Recruiting
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Enrollment
140 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

myelodysplastic syndrome (2) previously treated myelodysplastic syndrome (2) aplastic anemia (1) acute biphenotypic leukemia (1) acute myeloid leukemia (1) blast phase chronic myelogenous leukemia bcr abl1 positive (1) blasts 10 percent or more of bone marrow nucleated cells (1) blasts 10 percent or more of peripheral blood white cells (1) recurrent acute myeloid leukemia (1) recurrent chronic myelogenous leukemia bcr abl1 positive (1) refractory acute myeloid leukemia (1) refractory chronic myelogenous leukemia bcr abl1 positive (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology